Gonzalez Joan Castaneda, Park Ki Wan, Evans Dallin Brian, Sharma Rishi, Sahaym Om, Gopalakrishnan Shamila, Dar Aqib Iqbal, Valdez Tulio A, Sharma Anjali
Department of Chemistry, College of Arts and Sciences, Washington State University, Pullman, Washington, USA.
Department of Otolaryngology-Head & Neck Surgery Divisions, Stanford University School of Medicine, Stanford, California, USA.
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2025 Mar-Apr;17(2):e70010. doi: 10.1002/wnan.70010.
Nucleic acid (NA) therapy holds tremendous potential for treating a wide range of genetic diseases by the delivery of therapeutic genes into target cells. However, significant challenges exist in safely and effectively delivering these genes to their intended locations. Viral vectors, though efficient, pose risks such as immunogenicity and mutagenesis. This has resulted in growing interest in non-viral, nanoparticle-based NA delivery systems. This review article describes various physiological barriers to NA delivery and explores nanoparticle-based NA delivery systems, including bioengineered nanoparticles, peptides, lipid nanoparticles, and polymeric nanoparticles, highlighting their unique features to overcome in vivo barriers for NA delivery. While these nanoparticle-based NA delivery systems offer a promising alternative to viral vectors, challenges related to cytotoxicity, reproducible synthesis, and cost need to be addressed. The current clinical landscape of NA delivery is also discussed, emphasizing the need for safer, scalable, and cost-effective solutions. Nanoparticles represent a promising future in NA therapy, with the possibility of developing clinically relevant, non-toxic, stable, and non-immunogenic delivery vehicles, paving the way for broader therapeutic applications and improved clinical outcomes.
核酸(NA)疗法通过将治疗性基因传递到靶细胞中,在治疗多种遗传疾病方面具有巨大潜力。然而,在将这些基因安全有效地传递到预期位置方面存在重大挑战。病毒载体虽然高效,但存在免疫原性和诱变等风险。这使得人们对基于纳米颗粒的非病毒NA递送系统的兴趣日益增加。这篇综述文章描述了NA递送的各种生理屏障,并探讨了基于纳米颗粒的NA递送系统,包括生物工程纳米颗粒、肽、脂质纳米颗粒和聚合物纳米颗粒,强调了它们克服体内NA递送屏障的独特特性。虽然这些基于纳米颗粒的NA递送系统为病毒载体提供了一种有前景的替代方案,但与细胞毒性、可重复合成和成本相关的挑战仍需解决。文章还讨论了NA递送的当前临床情况,强调了对更安全、可扩展且具有成本效益的解决方案的需求。纳米颗粒在NA疗法中代表着一个有前景的未来,有可能开发出与临床相关、无毒、稳定且无免疫原性的递送载体,为更广泛的治疗应用和改善临床结果铺平道路。